阻止β2-AR和抑制COX-2:一种有希望的方法来抑制OSCC的发展
Zeliu Huang1, Laifeng Huang1, Chong Zhang1
1Department of Oral and Maxillofacial Surgery, College and Hospital of Stomatology, Guangxi Medical University, Nanning, Guangxi, China; Guangxi Key Laboratory of Oral and Maxillofacial Rehabilitation and Reconstruction, Nanning, Guangxi, China; Guangxi Key Laboratory of Oral and Maxillofacial Surgery Disease Treatment, Nanning, Guangxi, China; Guangxi Clinical Research Center for Craniofacial Deformity, Nanning, Guangxi, China.
阻断β2-上腺素受体 (β2-AR) 和循环氧化酶-2 (COX-2) 一起通过降低关键基因的调节,显著抑制口腔状细胞癌 (OSCC) 的发展. 这种组合疗法在治疗OSCC方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在口腔状细胞癌 (OSCC) 中,β2-上腺素受体 (β2-AR) 和循环氧化酶-2 (COX-2) 过度表达.
- 这些分子与OSCC的发展和进展有关.
研究的目的:
- 研究β2-AR阻断和COX-2抑制对OSCC抑制的协同效应.
- 评估联合治疗对OSCC细胞入侵,转移和体内瘤生长的影响.
主要方法:
- 实验室试验 (伤口愈合,穿孔入侵) 和西部斑/ELISA用于评估OSCC细胞行为和基因表达.
- 建立了体内OSCC异种移植模型,以评估存活率,瘤大小和转移.
- 免疫组织化学,西部斑块和ELISA被用于分析体内基因表达.
主要成果:
- 结合β2-AR阻断和COX-2抑制在体外显著抑制OSCC细胞的入侵和转移.
- 联合治疗降低了关键基因的调节,包括EGFR,TGF-β1,IL-1β,MMP2和VEGFA.
- 在体内,联合疗法延长了生存时间,抑制了瘤生长,减少了淋巴结转移,并降低了这些基因的调节.
结论:
- 结合β2-AR阻断和COX-2抑制的联合治疗有效地抑制了OSCC的发展.
- 这种方法降低了参与入侵和转移的关键基因 (EGFR,TGF-β1,IL-1β,MMP2,VEGFA) 的下调.
- 研究结果表明,这种组合是一种有前途的OSCC辅助疗法,利用成熟的药物.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
相关概念视频
Antihypertensive Drugs: Types of β-Blockers
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
